Thalidomide in front line treatment in multiple myeloma: serious risk of venous thromboembolism and evidence for thromboprophylaxis

J Thromb Haemost. 2004 Nov;2(11):2063-5. doi: 10.1111/j.1538-7836.2004.00931.x.
No abstract available

Publication types

  • Clinical Trial
  • Comparative Study
  • Letter
  • Multicenter Study
  • Randomized Controlled Trial

MeSH terms

  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Fibrinolytic Agents / therapeutic use
  • Humans
  • Multiple Myeloma / complications*
  • Multiple Myeloma / drug therapy*
  • Risk Factors
  • Thalidomide / adverse effects*
  • Thalidomide / therapeutic use*
  • Thromboembolism / chemically induced
  • Thromboembolism / prevention & control
  • Treatment Outcome
  • Venous Thrombosis / chemically induced*
  • Venous Thrombosis / prevention & control

Substances

  • Fibrinolytic Agents
  • Thalidomide